Flibanserin
- PMID: 26873507
- DOI: 10.1177/0897190016630409
Flibanserin
Abstract
Objective: To review pivotal clinical trials, pharmacology, contraindications, precautions, and key patient education points of flibanserin for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
Data sources: A literature search of PubMed using the key words flibanserin and HSDD was conducted in September 2015. There was no time frame to exclude relevant clinical trials. All trials referenced were published between March 2012 and June 2014. Other relevant information was obtained from the Food and Drug Administration (FDA) Web site, press releases, prescribing information from the manufacturer, and ClinicalTrials.gov .
Study selection/data extraction: All articles in the English language and involving human subjects were reviewed.
Data synthesis: There are three 24-week, multicenter, randomized, double-blind, placebo-controlled trials that evaluated the efficacy of flibanserin in North American premenopausal women with HSDD. There was 1 trial that studied the effects of flibanserin in postmenopausal women. In all of the trials, the investigators found statistical significant improvements in Female Sexual Function Index (FSFI) desire domain score and satisfying sexual events (SSEs). The most frequently reported adverse events in all flibanserin arms of treatment were somnolence, dizziness, and nausea.
Conclusion: Flibanserin, a novel, nonhormonal agent that modulates excitatory and inhibitory neurotransmitters was studied in premenopausal women and has shown efficacy in improving sexual desire and SSEs.
Keywords: flibanserin; hypoactive sexual desire disorder; premenopausal women.
Similar articles
-
Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder: Results of the PLUMERIA Study.J Sex Med. 2017 Jun;14(6):834-842. doi: 10.1016/j.jsxm.2017.03.258. J Sex Med. 2017. PMID: 28583342 Clinical Trial.
-
Flibanserin for Premenopausal Hypoactive Sexual Desire Disorder: Pooled Analysis of Clinical Trials.J Womens Health (Larchmt). 2019 Jun;28(6):769-777. doi: 10.1089/jwh.2018.7516. Epub 2019 Feb 1. J Womens Health (Larchmt). 2019. PMID: 30707049
-
Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis.JAMA Intern Med. 2016 Apr;176(4):453-62. doi: 10.1001/jamainternmed.2015.8565. JAMA Intern Med. 2016. PMID: 26927498 Review.
-
Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial.J Sex Med. 2013 Jul;10(7):1807-15. doi: 10.1111/jsm.12189. Epub 2013 May 14. J Sex Med. 2013. PMID: 23672269 Clinical Trial.
-
First Pharmacological Therapy for Hypoactive Sexual Desire Disorder in Premenopausal Women: Flibanserin.Ann Pharmacother. 2016 Feb;50(2):125-32. doi: 10.1177/1060028015622182. Epub 2015 Dec 20. Ann Pharmacother. 2016. PMID: 26692273 Review.
Cited by
-
Intranasal Niosomal In Situ Gel as a Promising Approach for Enhancing Flibanserin Bioavailability and Brain Delivery: In Vitro Optimization and Ex Vivo/In Vivo Evaluation.Pharmaceutics. 2020 May 27;12(6):485. doi: 10.3390/pharmaceutics12060485. Pharmaceutics. 2020. Retraction in: Pharmaceutics. 2024 Jan 29;16(2):189. doi: 10.3390/pharmaceutics16020189. PMID: 32471119 Free PMC article. Retracted.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical